CRT 2025

Q&A with the Panel

Panel Moderator(s)

• 

  Marc Cohen, MD

  Chair of Medicine
  Newark Beth Israel Med Ctr
  Philadelphia, Pennsylvania, United States

  Disclosure(s): Abbott Vascular, Edwards, Medtronic, Boston Scientific: Grant/Research Support (Ongoing); BSC, Amgen, BCRI, PERC, NAMSA, BMS, Janssen, Regeneron: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Daiichi Sankyo, Boeringer Ingelheim , Sanofi, AstraZeneca , Chiesi, Bracco, Amgen, Novo Nordisk, Philips: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  C. Michael Gibson, MD

  Professor of Medicine
  Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States

  Disclosure information not submitted.
• 

  Neal S. Kleiman, MD, FACC, MSCAI

  Medical Director, Cardiac Catheterization Laboratories
  Houston Methodist DeBakey Heart and Vascular Center
  Houston, Texas, United States

  Disclosure information not submitted.

Panel Discussant(s)

• 

  Usman Baber, MD, MS

  Professor of Medicine
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma, United States

  Disclosure information not submitted.
• 

  Sukhdeep S. Bhogal, MD

  Interventional Cardiologist
  Sovah Health
  Roanoke, Virginia, United States

  Disclosure(s): No financial relationships to disclose
• 

  Srihari S. Naidu, MD, FSCAI

  Director, Cath Labs and HCM Program
  Westchester Medical Center
  Valhalla, New York, United States

  Disclosure(s): No financial relationships to disclose
• MP

  Megha Prasad, MD

  Assistant professor
  Columbia university

  Disclosure information not submitted.
• 

  Robert S. Rosenson, MD

  Director of Metabolism and Lipids
  Mount Sinai Health System
  New York, New York, United States

  Disclosure(s): Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Avilar Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Editas Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing); GSK: Consulting Fees (e.g., advisory boards) (Ongoing); Intercept Pharmaceuticals Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Kowa American Corporation: Non-promotional lecture (Ongoing); Life Extension: Consulting Fees (e.g., advisory boards) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); MediMergent LLC: Stock-privately held company (Ongoing); New Amsterdam: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Organon: Consulting Fees (e.g., advisory boards) (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Rona Therapeutics, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve: Consulting Fees (e.g., advisory boards) (Ongoing); Viatris: Non-promotional lecture (Ongoing); William Blair: Consulting Fees (e.g., advisory boards) (Ongoing); Wolters Kluwer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
• JR

  Jennifer Rymer, MD

  Interventional cardiologist
  Duke, North Carolina, United States

  Disclosure information not submitted.